A global pharmaceutical company headquartered in Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.
The firm is currently looking for innovative therapeutics targeting cardiovascular-metabolic diseases including obesity, heart failure, metabolic abnormality-induced vascular dysfunction, kidney protection, and stroke. The firm also seeks new treatments for the following indications: sensory neuronal system conditions such as retinal and cochlear degeneration; pain relief through Mu-opioid receptor-dependent and non-opioid mechanisms; immune dysfunctions through mechanisms of homeostatic inflammation, APC, inflammatory factor and B cell function; and fibrosis of lung and the digestive system. However the firm is not interested in the triggers of fibrosis such as inflammation or viral infection. In addition, the firm is interested in muscle atrophy, anemia, and rare/serious diseases.
The firm is looking to partner with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment